IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VIGANO', MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.556
NA - Nord America 5.575
AS - Asia 5.455
SA - Sud America 460
AF - Africa 141
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 12
Totale 20.217
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.397
GB - Regno Unito 3.630
CN - Cina 1.873
SG - Singapore 1.610
DE - Germania 1.120
IT - Italia 855
SE - Svezia 647
RU - Federazione Russa 564
HK - Hong Kong 452
VN - Vietnam 427
FR - Francia 406
UA - Ucraina 346
IN - India 332
BR - Brasile 285
TR - Turchia 227
NL - Olanda 211
IE - Irlanda 198
KR - Corea 192
FI - Finlandia 165
EU - Europa 130
PL - Polonia 120
CA - Canada 110
CO - Colombia 88
DK - Danimarca 85
JP - Giappone 65
BD - Bangladesh 55
GR - Grecia 55
BE - Belgio 51
ID - Indonesia 44
AR - Argentina 38
MX - Messico 35
CI - Costa d'Avorio 34
ES - Italia 25
IQ - Iraq 24
UZ - Uzbekistan 21
PH - Filippine 20
TH - Thailandia 19
RO - Romania 16
VE - Venezuela 15
AU - Australia 14
EG - Egitto 13
SA - Arabia Saudita 12
ZA - Sudafrica 12
CH - Svizzera 11
EC - Ecuador 11
KE - Kenya 11
MY - Malesia 11
TN - Tunisia 11
SL - Sierra Leone 10
AT - Austria 9
DZ - Algeria 9
ET - Etiopia 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
PK - Pakistan 8
PT - Portogallo 7
CZ - Repubblica Ceca 6
IL - Israele 6
LK - Sri Lanka 6
MA - Marocco 6
PA - Panama 6
TT - Trinidad e Tobago 6
GH - Ghana 5
IR - Iran 5
JO - Giordania 5
UY - Uruguay 5
GE - Georgia 4
KZ - Kazakistan 4
PE - Perù 4
RS - Serbia 4
BG - Bulgaria 3
BO - Bolivia 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
LU - Lussemburgo 3
LY - Libia 3
MD - Moldavia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
PY - Paraguay 3
TW - Taiwan 3
BF - Burkina Faso 2
CR - Costa Rica 2
CU - Cuba 2
EE - Estonia 2
GT - Guatemala 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MM - Myanmar 2
NI - Nicaragua 2
PR - Porto Rico 2
QA - Qatar 2
RE - Reunion 2
SD - Sudan 2
SI - Slovenia 2
AD - Andorra 1
Totale 20.304
Salva come PNG Salva come JPEG
Città #
Southend 3.430
Singapore 950
Chandler 619
Ashburn 581
Hong Kong 412
Beijing 411
Frankfurt am Main 326
Seattle 315
Jacksonville 302
Milan 292
San Jose 269
Princeton 232
Dublin 184
Wilmington 177
Ann Arbor 153
Los Angeles 151
Nanjing 144
Bengaluru 139
Council Bluffs 136
Santa Clara 136
Hanoi 132
Ho Chi Minh City 132
Mountain View 131
Dearborn 115
Redmond 115
New York 111
Dallas 106
Warsaw 103
Lauterbourg 94
Serra 91
Andover 80
Fairfield 80
Boardman 79
Sakarya 79
Des Moines 78
Bogotá 77
Toronto 77
Moscow 74
Shanghai 73
Buffalo 69
Woodbridge 64
Helsinki 56
Somerville 56
Guangzhou 52
Jinan 50
Munich 50
Tianjin 45
Hebei 44
Shenyang 44
Tokyo 41
Brussels 40
Hefei 40
Athens 39
Phoenix 38
Grafing 37
Nanchang 36
Abidjan 34
Cangzhou 34
São Paulo 34
Houston 33
Saint Petersburg 33
Zhengzhou 30
Chicago 28
Rome 28
Hangzhou 27
Redwood City 27
Kiez 26
Da Nang 25
Berlin 24
Bitonto 24
Mumbai 24
Changsha 23
Turin 23
Seoul 20
Columbus 19
Fuzhou 19
Haiphong 19
Nürnberg 18
San Diego 18
The Dalles 18
Fremont 17
Shenzhen 17
Istanbul 16
Kunming 15
Chennai 14
London 14
Menlo Park 14
Nuremberg 14
Orem 14
Central District 13
Jiaxing 13
Turku 13
Eitensheim 12
Jakarta 12
Palaiseau 12
Washington 12
Cambridge 11
Delhi 11
Düsseldorf 11
Palermo 11
Totale 12.861
Salva come PNG Salva come JPEG
Nome #
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 440
Real life experiences in HCV management in 2018 393
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 389
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice : high efficacy and favorable safety profile over 3 years of treatment 341
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 303
Combined lamivudine and adefovir dipivoxil treatment allows safe and long-term compath-1H therapy in refractory B-cell chronic lymphocytic leukemia with HBV reactivation 297
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H 290
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 287
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 280
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 264
Accuracy of two new predictive models in assessing fibrosis in chronic hepatitis C (CHC) 258
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 255
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients 253
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease 249
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 242
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 241
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 241
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 240
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 238
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 238
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 237
Evaluating liver fibrosis in chronic hepatitis c (CHC), accuracy of two new predictive models 234
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 234
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 232
Clinical implications of HBsAg quantification in patients with chronic hepatitis B 231
Inhibition of HBV-replication by combined treatment of lamivudine and adefovir dipivoxil allows long-term campath-1H therapy in refractory B-cell chronic lymphoblastic leukemia 229
Lamivudine prophylaxis of hepatitis B reactivation in anti-HBC seroposivive patients undergoing chemotherapy for onco-hematological diseases 228
Combination therapy with adefovir dipivoxil (ADV)and lamivudine (LAM) in LAM-resistant patients enlisted for liver transplantation 225
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 224
Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis 223
Severe hepatic fibrosis in chronic hepatitis C 221
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 216
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 210
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 208
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 208
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma 207
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 207
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 206
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues 204
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 204
Transient elastography predicts response to prolonged therapy with a nucleoside analog in patients with chronic hepatitis B 201
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 198
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic hepatitis B 196
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 194
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 194
Very early add-on adefovir therapy in patients with sub-optimal virological response to lamivudine 193
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 192
PegBeLiver study : HBsAg decline at week 24 of extended Peginterferon Alfa-2A (PEG-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype D patients 191
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients 191
No evidence for ADV resistance in HBeAg-negative Lamivudine resistant patients treated with LAMIVUDINE-ADEFOVIR combination for 3 years 190
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 190
Ruolo delle crioglobuline sieriche nel corso dell'epatopatia cronica HCV-correlata. Studio prospettico di coorte di 343 pazienti 189
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 187
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 186
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study 186
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients 185
No evidence for ADV resistance in HBeAg negative lamivudine resisstant patients treated with lamivudine-adefovir combination for 3 years 183
Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation 181
Protocol liver biopsies to evaluate severity of recurrent HCV hepatitis : a recent monocentric experience 181
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 181
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 179
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants 177
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 176
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 174
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 174
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis 173
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 173
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 173
Acute hepatitis following assumption of a herbal remedy 170
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 168
A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C : a comparison using histology with internal-external validation 168
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 168
Graft dysfunction (GD) in HBV recurrence free recipience is associated with serum autoantibodies reactivity 168
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 167
Late graft dysfunction (GD) in HBV recurrence-free recipients is associated with serum antinuclear antibodies (ANA) reactivity 166
Entecavir for nuc-naïve chronic hepatitis b patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 166
Low risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis : a retrospective multicenter Italian study 163
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal 161
Failure of adefovir 20 mg to improve suboptimal response in lamivudine resistant hepatitis B patients treated with adefovir 10 mg and lamivudine 157
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs) 156
Optimal therapy of chronic hepatitis B : how do I treat my HBeAg-negative patients? 154
Efficacy and safety of pegylated interferon plus ribavirin in patients with hepatitis C recurrence after liver transplantation : a single centre experience 152
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients 150
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 149
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 147
High rates of hepatitis B virus riverse seroconversion in anti-HBc carriers undergoing allogeneic bone marrow transplantation 146
Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders 146
AISF position paper on HCV in immunocompromised patients 146
Systematic review with meta-analysis : do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? 144
Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40kd] in genotype D patients with HBeAg-negative chronic hepatitis B 143
The prognosis and management of inactive HBV carriers 142
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy 140
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma 138
Review article : The potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection 137
PegIFN-α2a for the treatment of chronic hepatitis B and C : a 10-year history 136
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 135
Low risk of hepatocellular carcinoma recurrence after liver transplantation : a 3-year follow-up study in 78 patients with chronic hepatitis B 129
Maintained HBV suppression in lamivudine-resistant patients treated with adefovir and lamivudine combination : A 4- year cohort study in 63 patients 129
Six years of "on demand" LAM plus ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 128
Progressive decline of HBsAg titers in long-term virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 126
Totale 20.110
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.215
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.215
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021628 0 0 0 0 0 0 0 0 0 0 412 216
2021/20221.426 127 79 73 94 62 66 121 121 131 210 81 261
2022/20231.796 230 224 142 251 195 349 33 88 176 29 52 27
2023/20241.205 29 82 39 55 329 118 76 90 38 68 126 155
2024/20252.438 99 276 64 307 217 58 30 218 152 190 241 586
2025/20264.656 583 293 458 318 528 369 670 232 467 457 281 0
Totale 21.284